ArticlePsoriasis (Auckland, N.Z.)2026
Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP-GPP Overlap.
Article in Psoriasis (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Effectiveness of Secukinumab in Congenital Ichthyoses: A Retrospective Monocentric Case Series.Antibodies (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric erythroderma can arise from either inherited keratin defects or cytokine-driven inflammation, yet evidence for biologic therapies in these settings is limited. We report two rare pediatric cases successfully treated with secukinumab, an IL17A-targeted monoclonal antibody: (i) a 2-year-old boy with genetically confirmed epidermolytic ichthyosis (EI, KRT10 mutation:c.467G>A, p.Arg156His) refractory to conventional care, who achieved >60% improvement in erythema and scaling one week after a single off-label 150 mg subcutaneous secukinumab dose, with remission maintained for 12 months on monthly dosing; and (ii) an 11-year-old girl with coexistent Type III (juvenile) pityriasis rubra pilaris and acute generalized pustular psoriasis (PRP-GPP overlap) unresponsive to acitretin and methotrexate, who attained complete remission for 12 months following standard secukinumab induction (300mg weekly ×5) and maintenance every four weeks. These cases extend the potential utility of IL17A blockade beyond psoriasis vulgaris to both structural keratinopathies and inflammatory pustular dermatoses in children. While limited by the nature of a two-patient case series, these findings warrant prospective studies to clarify optimal dosing and long-term safety of IL-17A blockade in pediatric dermatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.